Was Actavis approved to sell fidaxomicin in Europe?
Fidaxomicin (the branded drug Dificlir/Dificlir is referenced in European materials) has been authorised in Europe by national/European regulatory routes, but the provided information does not specify that “Actavis labs” is the marketing authorisation holder for fidaxomicin in Europe. Without the missing regulatory details (authorisation holder name, product strength/form, and country), it is not possible to confirm an “Actavis labs” approval status from the information given.
Which Actavis entity would matter for a Europe approval?
In Europe, approval and “who is approved” depend on the legal entity holding the marketing authorisation and the specific product presentation (strength and dosage form). “Actavis labs” could also refer to a company group name that differs from the marketing-authorization holder name printed on the Summary of Product Characteristics (SmPC).
How to check the exact Europe approval (and who holds it) for fidaxomicin
To verify whether Actavis is the approved company for fidaxomicin in Europe, you typically need one of the following:
- The product’s SmPC or package leaflet for the country of interest, which lists the marketing authorisation holder.
- A Europe-wide regulatory search (by active substance and product name) to identify the marketing authorisation holder and approval date.
- A national medicines register entry (if the authorisation is national rather than centrally authorised).
Does Europe use the same brand name and formulation across countries?
Fidaxomicin approval can vary by:
- Country (different national registers)
- Pack size
- Dosage strength
- Marketing authorisation holder name on the label
So “approval in Europe” can be true for fidaxomicin overall while still being false for a specific company name like “Actavis labs,” depending on who holds the authorisation for the particular product listing.
What I need from you to give a definitive answer
If you share any one of the following, I can pinpoint the “Actavis labs” Europe approval status precisely:
- The exact country (e.g., UK, Germany, France, Spain, Italy, etc.)
- The brand name used there for fidaxomicin (or the product page link)
- The dosage form/strength (e.g., tablets 200 mg)
- Whether you mean marketing authorisation or product launch/sales approval
Sources: none provided in the prompt.